

Angélique Gougelet, PhD

Born on March 13th, 1980 at Châtenay-Malabry, France
Centre de Recherche des Cordeliers-Umrs1138
15 rue de l'école de médecine
75006 Paris
01 44 27 60 36
angelique.gougelet@inserm.fr

ACTUAL POSITION

“Chargé de Recherche Classe Normale” since october 2015

EDUCATION

10/2010-10/2015: Post-doctoral Fellow, INSERM U1016, Institut Cochin, Paris, France
05/2007-07/2010: Post-doctoral Fellow, INSERM U590, Centre Léon Bérard, Lyon, France
01/2004-01/2007: PhD in Biology, Paris XI University, Châtenay-Malabry, France

TRAINING & TEACHING

- Internships of 17 students, 2 PhD students
- Teaching in L3 Pro « Microbiologie Industrielle et Biotechnologies » (2011-now) and M1 “Magistère Européen de Génétique” (2019-now), Université Paris Cité
- Organizer of workshops for the “Fête de la Science” (2016-2018, 2021) and for young students from “Envol” association (2016-now)

SCIENTIFIC EXPERTISE

- Editorial member of the “World Journal of Hepatology” Journal since April 2018
- Reviewing of more than 100 international manuscripts (*Gut, Liver International, Journal of Hepatology, Hepatology, International Journal of Hepatology...*)
- Expert for a grant for AFEF, National Science Centre Poland, Ligue Nationale contre le Cancer, Telethon Grant in Italy and a grant for the Israel Science Foundation
- Reporter of four theses, five “Comité de suivi de thèse”, one « Maitre de Conférences » recruitment examination
- Member of the selection committee for abstracts during AFEF meeting 2020
- Member of the organizing committee for seminars in Centre de Recherche des Cordeliers
- Representative of the “Chargé de Recherche” in Cochin Institute
- Speaker in 20 meetings, invited in 6

FUNDINGS

- PLBIO21 « Liver resident macrophages: key actors in the pathogenesis of hepatocellular carcinoma” (2022-2025)
- ANR JCJC « β -catenin-mediated epigenetic control of the imprinted DLK1/Dio3 locus in liver” (2018-2021)
- AAP Association Française d'Etude du Foie 2018

PRIZE AND DISTINCTIONS

- APEMM Prize for the best manuscript in 2015
- Young investigator Bursaries in EASL 2013 and EASL HCC summit 2014
- Young researcher Bursaries in AFEF 2013
- Prize of the best talk in the Wnt meeting 2010

PUBLICATIONS

ORCID number: 0000-0001-7464-9804, **Scopus Author ID:** 8737049800
16 international manuscripts, 11 international reviews, 2 book chapters



ORCID iD profile for Angelique Gougelet. The profile includes a circular logo with the initials 'AG', a 'Web of Science ResearcherID' badge (E-2071-2017), and a table of academic metrics:

PUBLICATIONS	TOTAL TIMES CITED	H-INDEX	VERIFIED REVIEWS
30	756	11 [®]	84

Below the table is a 'Follow' button and a 'Citée par' section showing citation statistics:

Citée par	Toutes
Citations	1114
indice h	14
indice i10	17

Additional information includes the name 'angelique Gougelet', affiliation 'Centre de Recherche des Cordeliers', and email 'Adresse e-mail validée de inserm.fr'.

International manuscripts

Loesch R, Caruso S, Paradis V, Godard C, **Gougelet A**, Renault G, Picard S, Tanaka I, Renoux-Martin Y, Perret C, Taketo MM, Zucman-Rossi J, Colnot S. Deleting the β -catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth. *J Hepatol*. 2022 Mar 4:S0168-8278(22)00130-1. doi: 10.1016/j.jhep.2022.02.023.

M. Cadoux, S. Caruso, S. Pham, **A. Gougelet**, ... and J-P. Couty. NKG2D ligands expression is down regulated by beta-catenin signalling and correlates with HCC aggressiveness in mice and human. *J.Hepatol*. 2021 Jan 20:S0168-8278(21)00028-3. doi: 10.1016/j.jhep.2021.01.017.

R. Riou, M. Ladli, S.Gerbal-Chaloin, P. Bossard, **A. Gougelet**... and S. Colnot. ARID1A loss in adult hepatocytes unleashes β -catenin-mediated erythropoietin transcription. *eLife*. 2020 Oct 21;9:e53550. doi: 10.7554/eLife.53550.

A. Gougelet*, C. Sartor*, N. Senni*, ... and S.Colnot. Hepatocellular Carcinomas With Mutational Activation of Beta-Catenin Require Choline and Can Be Detected by Positron Emission Tomography *Gastroenterology*. 2019; 157 (3): 807-822. doi: 10.1053/j.gastro.2019.05.069.

C. Sartor, ..., **A. Gougelet*** and S. Colnot*. The concomitant loss of APC and HNF4 α in adult hepatocytes does not contribute to hepatocarcinogenesis driven by β -catenin activation. *Liver Int*. 2019; 39 (4): 727-739. doi: 10.1111/liv.14068* AG and SC contributed equally to this work

Senni N, Savall M, Cabrerizo Granados D, Alves-Guerra MC, Sartor C, Lagoutte I, **Gougelet A**, Terris B, Gilgenkrantz H, Perret C, Colnot S, Bossard P. β -catenin-activated hepatocellular carcinomas are addicted to fatty acids. *Gut*. 2018; 68 (2): 322-334. doi: 10.1136/gutjnl-2017-315448.

A. Gougelet, C. Sartor, L. Bachelot, *et al*. Antitumor activity of an inhibitor of miR-34a in liver cancer mutated for β -catenin. *Gut*. 2016; 65:6 1024-1034. doi: 10.1136/gutjnl-2014-308969.

A. Gougelet, C.Torre, P.Veber, *et al*. T-cell factor 4 and β -catenin chromatin occupancies pattern zonal liver metabolism. *Hepatology*. 2014 Jun; 59(6): 2344-57. doi: 10.1002/hep.26924.

Anson M, Crain-Denoyelle AM, Baud V, Chereau F, **Gougelet A**, *et al*. Oncogenic β -catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. *J Clin Invest*. 2012 Feb 1; 122(2): 586-99. doi: 10.1172/JCI43937.

Gougelet A, Perez J, Pissaloux D, *et al*. miRNA profiling: How to Bypass the Current Difficulties in the Diagnosis and Treatment of Sarcomas. *Sarcoma*. 2011; 2011:460650.

Gougelet A, Pissaloux D, Besse A, *et al*. Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. *Int J Cancer*. 2011 Aug 1; 129(3): 680-90.

Gougelet A, Mansuy A, Blay JY, *et al*. Lymphoma and myeloma cell resistance to cytotoxic agents and ionizing radiations is not affected by exposure to anti-IL-6 antibody. *PLoS One*. 2009 Nov 30; 4(11): e8026.

Gougelet A., Mueller S. O., Korach K. S. and Renoir J-M. E strogen receptor (ER) pathways to E strogen response elements: the transactivation function AF-1 acts as the keystone of ER-mediated transcription repression of ER. *J. Steroid Biochem Mol Biol*, 2007. 104(3-5): 110-22.

Gougelet A., Bouclier C., Marsaud V., *et al*. Estrogen receptor and subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells. *J. Steroid Biochem Mol Biol*, 2005. 94 (1-3): 71-81.

Maillard S, Ameller T, Gauduchon J, **Gougelet A**, *et al*. Innovative drug delivery nanosystems improve the anti-tumor activity in vitro and in vivo of anti-estrogens in human breast cancer and multiple myeloma. *J Steroid Biochem Mol Biol*. 2005 Feb; 94(1-3): 111-21.

Marsaud V., **Gougelet A.**, Maillard S. and Renoir J.M. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ER), differentially affect ER extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells. **Mol Endocrinol**, 2003. 17: 2013-27.

International reviews

J. Sanceau and **Gougelet A.** Epigenetic mechanisms of liver tumor resistance to immunotherapy. **World J Hepatol**. 2021 Sep 27;13(9):979-1002. doi: 10.4254/wjh.v13.i9.979.

Gougelet A, Colnot S. Une Imagerie métabolique des cancers primitifs du foie basée sur leur addiction à la Choline permet de prédire leur oncogénotype, et de proposer une piste thérapeutique. **Med Sci (Paris)**. 2020 Apr;36(4):322-326. doi: 10.1051/medsci/2020051.

A. Gougelet and C. Desbois-Mouthon. Non-coding RNAs Open a New Chapter in Liver Cancer Treatment. **Clin Res Hepatol Gastroenterol**. 2019, 43 (6): 630-637. 10.1016/j.clinre.2019.07.005

A. Gougelet. Epigenetic modulation of immunity: towards new therapeutic avenues in hepatocellular carcinoma? **Gut**. 2019; 68 (10): 1727-1728. doi: 10.1136/gutjnl-2019-319084.

A. Gougelet. Exosomal microRNAs as a potential therapeutic strategy in hepatocellular carcinoma. **World J Hepatol**. 2018; 10(11): 785-789. doi : 10.4254/wjh.v10.i11.785.

Lechel A and **Gougelet A.** Early HCC treatment: a future strategy against interferon/miR-484 axis to revert precancerous lesions? **Gut**. 2016 Mar 4. 65: (7) 1073-1074. doi: 10.1136/gutjnl-2016-311446.

Gougelet A, Colnot S. Hepatocellular carcinoma diagnosis: Circulating microRNAs emerge as robust biomarkers. **Clin Res Hepatol Gastroenterol**. 2016 Sep; 40(4): 367-9. doi: 10.1016/j.clinre.2015.12.010.

Gougelet A, Colnot S. Les microARN dans le cancer du foie: à l'orée de nouvelles thérapies ciblées? **Med Sci (Paris)**. 2013 Oct; 29(10): 861-7. doi: 10.1051/medsci/20132910013.

Gougelet A, Colnot S. MicroRNA-feedback loop as a key modulator of liver tumorigenesis and inflammation. **World J Gastroenterol**. 2013 Jan 28; 19(4): 440-4. doi: 10.3748/wjg.v19.i4.440.

Gougelet A, Colnot S. A Complex Interplay between Wnt/ β -Catenin Signalling and the Cell Cycle in the Adult Liver. **Int J Hepatol**. 2012; 2012:816125. doi: 10.1155/2012/816125.

Gougelet A., Mansuy A. et J-Y Blay. De l'eau au moulin de thérapies ciblant l'interleukine-6 dans les tumeurs épithéliales. **Med&Sciences**, 2008 Aug-Sep; 24(8-9): 694-6.

Book chapter

Gougelet A, Colnot S. Chapter 8: MicroRNAs linking cancer and inflammation: focus on liver cancer in the book "MicroRNAs: Key Regulators of Oncogenesis", Springer. DOI: 10.1007/978-3-319-03725-7_8

J. Sanceau and **Gougelet A.** Applications of Non-Coding RNAs in Liver Cancer Patients in the book "Clinical Applications of Non-Coding RNAs in Cancer" from Elsevier. DOI: 10.1016/B978-0-12-824550-7.00007-2